Sitesinformation.com

Keyword Analysis & Research: exelixis


Keyword Analysis

Keyword CPC PCC Volume Score Length of keyword
exelixis0.30.71198338

Keyword Research: People who searched exelixis also searched

Keyword CPC PCC Volume Score
exelixis0.680.5415258
exelixis stock1.180.7492079
exelixis careers1.70.8893281
exelixis inc stock price0.40.5707194
exelixis pharmaceuticals1.030.7819281
exelixis news1.340.5930681
exelixis pipeline0.150.2292484
exelixis sasmos0.760.1887724
exelixis logo1.170.1122090
exelixis yahoo finance0.620.8814495
exelixis glassdoor0.331945633
exelixis layoff0.430.5455527
exelixis address1.430.5586821
exelixis software0.530.1372766
exelixis alameda ca0.730.3278456
exelixis bioiatriki0.70.6509366
exelixis investor relations0.180.2764481
exelixis press release0.891225479
exelixis king of prussia pa address1.60.1234664
exelixis yahoo message board1.110.798089

Search Results related to exelixis on Search Engine

  • Shaping the Future of Oncology for Patients l Exelixis

    exelixis.com

    https://www.exelixis.com/

    WEBExelixis is an oncology-focused biotech company innovating cancer treatments for life. Find out how we're dedicated to giving more patients hope for the future.

    DA: 23 PA: 81 MOZ Rank: 3 Up or Down: Up

  • Exelixis - Wikipedia

    wikipedia.org

    https://en.wikipedia.org/wiki/Exelixis

    WEBExelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.

    DA: 93 PA: 98 MOZ Rank: 72 Up or Down: Up

  • Exelixis, Inc. (EXEL) Stock Price, News, Quote & History - Yahoo Finance

    yahoo.com

    https://finance.yahoo.com/quote/EXEL

    WEBFind the latest Exelixis, Inc. (EXEL) stock quote, history, news and other vital information to help you with your stock trading and investing.

    DA: 32 PA: 26 MOZ Rank: 51 Up or Down: Up

  • Building a Legacy of Oncology Excellence l Exelixis

    exelixis.com

    https://www.exelixis.com/our-story/

    WEBOur story is one of dedication to patients and scientific excellence. Throughout nearly three decades, we’ve evolved into a multi-platform cancer company. Today, we are innovating with both small molecules and biotherapeutics to build a diversified portfolio of cancer treatments that give patients hope for the future.

    DA: 89 PA: 65 MOZ Rank: 74 Up or Down: Up

  • Our Medicines for Cancer Patients l Exelixis

    exelixis.com

    https://www.exelixis.com/medicines/

    WEBIf you want to report a product quality complaint related to use of CABOMETYX or COMETRIQ, please call 1-855-500-3935 (EXEL). Medical information questions. If you are a healthcare professional and have a question about an Exelixis product, please contact Exelixis Medical Information at [email protected] or call 1-855-292-3935 (EXEL).

    DA: 31 PA: 25 MOZ Rank: 84 Up or Down: Up

  • Investors and News | Exelixis

    exelixis.com

    https://ir.exelixis.com/

    WEBJan 23, 2024 · Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update. 02/01/24. Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February. 01/25/24.

    DA: 95 PA: 79 MOZ Rank: 21 Up or Down: Up

  • Cancer Clinical Trials and Pipeline l Exelixis

    exelixis.com

    https://www.exelixis.com/clinical-trials-pipeline/

    WEBWe are advancing a diverse and promising portfolio of clinically differentiated compounds through internal development and strategic external partnerships. Clinical Trials. Pipeline. Phase 3. CONTACT-02. Prostate Cancer. Cabozantinib + atezolizumab vs. abiraterone + prednisone or enzalutamide. Phase 3. COSMIC-313.

    DA: 31 PA: 85 MOZ Rank: 36 Up or Down: Up

  • Advancing Science for Cancer Treatments l Exelixis

    exelixis.com

    https://www.exelixis.com/inside-exelixis/

    WEBAt Exelixis, the ultimate definition of success is our ability to help more patients living with cancer. Michael M. Morrissey, Ph.D. President and Chief Executive Officer. Discover how we're expanding our product portfolio and West and East coast footprints to propel oncology innovation forward.

    DA: 28 PA: 91 MOZ Rank: 28 Up or Down: Up

  • Exelixis Announces Initiation of the STELLAR-305 Phase 2/3 …

    exelixis.com

    https://ir.exelixis.com/news-releases/news-release-details/exelixis-announces-initiation-stellar-305-phase-23-pivotal-trial

    WEBDec 4, 2023 · Exelixis Announces Initiation of the STELLAR-305 Phase 2/3 Pivotal Trial Evaluating Zanzalintinib in Combination with Pembrolizumab in Patients with Previously Untreated Recurrent or Metastatic Head and Neck …

    DA: 96 PA: 57 MOZ Rank: 26 Up or Down: Up

  • Developing a Novel Pipeline of Cancer Therapies l Exelixis

    exelixis.com

    https://www.exelixis.com/discovery-engine/

    WEBData-driven and science-first. As we seek to improve the treatment of patients with cancer, Exelixis is addressing a broad array of targets selected based on rigorous scientific and clinical evidence with the goal of developing a diverse …

    DA: 24 PA: 42 MOZ Rank: 66 Up or Down: Up